Search results (62)
« Back to NewsMachine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation
11 August 2023
In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.
Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies
27 July 2023
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
Multi-cancer blood test shows real promise in NHS trial
2 June 2023
Clinical Trials Innovation Research Translational Research
An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.
The Howat Foundation to fund Chair in Clinical Oncology
10 May 2023
Awards & Appointments Department Innovation Research
Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation
New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years
6 April 2023
Innovation Publication Research
A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.
Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment
16 December 2022
Department Immunology Research
New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
Oxford gets £122m funding for healthcare research
14 October 2022
Funding Research Translational Research
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).
The Department represented at the European Radiation Research Society annual conference
30 September 2022
Events FLASH Radiation Research
Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.
Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene
29 September 2022
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.
Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine
5 August 2022
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.
Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis
29 June 2022
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination
24 May 2022
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
OUH agrees long COVID research collaboration with Polarean
18 May 2022
Research Translational Research
The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.
Lung abnormalities found in long COVID patients with breathlessness
29 January 2022
Research Translational Research
Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.
New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread
5 January 2022
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
Eileen Parkes secures Clinical Research Career Development Fellowship
16 December 2021
Eileen is awarded funding for her research into the tumour microenvironment
MP Anneliese Dodds tours Oxford cancer research
26 November 2021
Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
24 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.